Applied DNA Reports 2020 Fiscal Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Applied DNA Sciences (APDN) Misses Q2 EPS by 2c
May 14, 2020 4:33 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q2 EPS of ($0.79), $0.02 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $552.47 thousand versus the consensus estimate of $950 thousand.
Fiscal Second Quarter 2020 Financial Results:
Revenues decreased 29% for the second quarter of fiscal 2020 to $552 thousand, compared with $778 thousand reported in the same period of the prior fiscal year and decreased 13% from $634 for the first quarter of fiscal 2020. This decrease in revenues year over year is due to a decrease of $305 thousand in service revenues, offset by an increase of $79 thousand in product... More